NASDAQ: PRE - Prenetics Global Limited

Yield per half year: -27.45%
Dividend yield: 0.00%
Sector: Healthcare

Share chart Prenetics Global Limited


About Prenetics Global Limited

Prenetics Global Limited operates as a diagnostics and genetic testing company in Hong Kong and the United Kingdom. Its products include CircleDNA, a consumer genetic testing product; and Circle HealthPod, a rapid detection health monitoring device that offers COVID-19 testing solutions for professional use and home use.

more details
The company's products also comprise ColoClear, a non-invasive FIT-DNA colorectal cancer screening test; Circle SnapShot, an off-the-shelf at-home blood test; ACTOnco, a comprehensive test that helps clinicians choose the optimal treatment for all major solid tumors; ACTDrug+, a screening test that checks for 40 cancer genes to map drug options and provide treatment strategy options; ACTLung, a test focused on biomarkers associated with lung cancer for targeted therapy; ACTFusion, a test that decodes 13 fusion genes and more than 350 transcripts to map drug options; and ACTCerebra, a genomic profiling service for solid tumors. It also offers ACTMonitor, a test that analyzes 50 forms of circulating tumor DNA in the bloodstream; and ACT Risk, a screening of 67 cancer genes associated with 9 common hereditary cancers and 11 cancer syndromes. Prenetics Global Limited was founded in 2014 and is headquartered in Quarry Bay, Hong Kong.

IPO date 2022-05-18
ISIN KYG722451062
Industry Insurance
Sector Financials
Валюта usd
Валюта отчета usd
Сайт https://www.prenetics.com
Цена ао 3.86
Change price per day: -0.2695% (3.71)
Change price per week: +1.37% (3.65)
Change price per month: -18.14% (4.52)
Change price per 3 month: -36.32% (5.81)
Change price per half year: -27.45% (5.1)
Change price per year: +6.02% (3.49)
Change price per 3 year: -62.89% (9.97)
Change price per year to date: -34.46% (5.645)

Underestimation

Title Value Grade
P/S 2.83 6
P/BV 0.2927 10
P/E 0 0
EV/EBITDA -0.4065 0
Total: 5.75

Efficiency

Title Value Grade
ROA, % -24.68 0
ROE, % -30.4 0
Total: 0

Dividends

Title Value Grade
Div yield, % 0 0
DSI 0 0
Total: 1.35

Debt

Title Value Grade
Debt/EBITDA -0.053 10
Total: 9.8

Growth impulse

Title Value Grade
Yield Revenue, % 136.33 10
Yield Ebitda, % 158.9 10
Yield EPS, % 2964.52 10
Total: 10



Head Job title Payment Year of birth
Mr. Hoi Chun Lo Chief Financial Officer N/A 1985 (40 years)
Dr. Yung Ho Wong DPHIL Chief Technology Officer N/A 1982 (43 years)
Ms. Samantha Kwok Chief of Staff to Group CEO & Vice President of People & Operations N/A
Dr. Senthil Sundaram M.D. Chief Clinical Officer N/A 1974 (51 year)
Mr. Joel Neoh Chief Consumer Officer & CEO for CircleDNA N/A 1984 (41 year)
Mr. Sheng Wu Yeung Co-Founder, Chairperson & CEO N/A 1979 (46 years)
Dr. Chi Hung Tzang Ph.D. Co-Founder & Chief Scientific Officer N/A 1974 (51 year)
Mr. Walt Ling Chief Executive Officer of ACT Genomics N/A

Address: Hong Kong, Quarry Bay, Unit 701-706. K11 Atelier King’s Road - open in Google maps, open in Yandex maps
Website: https://www.prenetics.com